Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients
|
|
- Theodore Hamilton
- 5 years ago
- Views:
Transcription
1 Published Ahead of Print on November 10, 2016, as doi: /haematol Copyright 2016 Ferrata Storti Foundation. Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients by Sebastiaan D.T. Sassen, Ron A.A. Mathôt, Rob Pieters, Robin Q.H. Kloos, Valérie de Haas, Gertjan J.L. Kaspers, Cor van den Bos, Wim J.E. Tissing, Maroeska te Loo, Marc B. Bierings, Wouter J.W. Kollen, Christian M. Zwaan, and Inge M. van der Sluis Haematologica 2016 [Epub ahead of print] Citation: Sassen SDT, Mathôt RAA, Pieters R, Kloos RQH, de Haas V, Kaspers GJL, van den Bos C, Tissing WJE, te Loo M, Bierings MB, Kollen WJW, Zwaan CM, and van der Sluis IM. Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients. Haematologica 2016; 101: XXX doi: /haematol
2 W ^ d ^ d Z D d Z W d Z Y, < d s, d ' : > < d d e t : d e D > e D e t : t < dd D d / D ^ d d W K D ^, Z d E d, W D h d E d W D W K h d E d K ' K' d, d E d W K shh D d E e W K, D d E e W K, h D ' d E e W, K Z h E D E d E e W D d W h D h t, d E W /, K ^ d > h D > d E d
3 < > > W W EKEDD / D ^ D W D ^, W K, t ed Z E dede ddz d E d ld ddeddeeed & ld ddeddeedd Z W W< >> t d d eed e d d / ^ Z W / D ^ : W D d < < < < & ' d & d
4 K ' mddd/h > d d / e d de d ddd /h d EKEDD d / ddl ddl ddl md D ^ d ddd /h d d EdZddee d Z d
5 > >> > > h ^ ^ D > K' K ' 'K& ',, //s / /D / /Ks / /YZ / /h / h /h > / h > /h d / h /s / < < >> Y > EKEDD E D D K&s K W' W W< W Y / d d d, dd d s s sw s d
6 / >, d >> d e W' d e e > W< K ' K' >> >> dd ddd/h > e e dd ddd/h > de ddd/h > de E d W< / d d de de d de d de dd W' d
7 d d e e de dd e d e e dd e d e e dd d W< >> //s K/s W< Y //s dd /Ks ddd/h > D W d e E d de >> K'>> d E ddd dd >> d dddd h^ W d ddd/h d D t & d ^ ed mddd/h > >> ed mddd/h > t d dd d D ddde d & dd d de ed & e
8 d d >> Y md/h > de d /Z W d EKEDD d ^ W< K&s 'K& sw d ed K&s md d W< & d ed d de de / d K&s d K&s & ldd e
9 sw d D ldd Z W dd W< d >> Y K d edd d de d el l ld ld d ^ d ^ de dl ed de el & d d dd >> >> >> d e
10 dd dd d dd dee d /YZ dd ded d /h > ded d /YZ dd dee d /h > ed dl ed el mddd /h > ed del ed ddl mdd/h > d ed ed d dd de d /YZ de e de /h > ed e /YZ de d ee e /h > de dl de dl mddd/h > ddl ed dl mdd/h > d d ddd el d ee d d ed ddd /h > el ed mddd /h > dde dl W d W< ed k d K&s d K&s dde d dee d dde d md d d ed/h > d ed/h > D D e
11 d //s > del s Y s ed e d K&s //s > ddl ddl ^ /Ks ddl /Ks K&s e d ed d de //s > del ddl d el //s > ddl /Ks > el d d ddl de d K&s md d > md, dd ^ t K&s e md l ddl > l dd d ^ >> >> d d >d dd> ed s dd
12 d d > ed Y d dd > ed s d e> ed d d d d d d d d d d d de e d ddl d ddl d d d / d d d d D d eee dd d d d dddd d sw edl d d d de de ed ed ed, d ed ed dde ^ d D W< de W dd
13 d ddd/h dddd/h mddd/h > edl de d d t ddd /h d edl mdd mddd /h > de & ddd/h d dd ddd de ddd /h d mddd/h > de edl d edl ddd/h d d /h /h d ^ dd & d e /h /h d de mddd/h > d mdd/h > e ddl edl d W< ^ de ddd /h d de t dd dd del mdd d d ddl d mdd de ddd/h > D d W< W' dd d D W< d dd
14 >> ddl e de dd, dd W' d W< e de dd dd / E & dd / ^ W< e e dd d W< W< d W< dd d de e de d dd W e d e d dd, d d de e d d d dd
15 dd d, W< W< dd //s /Ks / //s ddl /Ks ddl W< d W< d //s d d sw ed dde d, t d D mddd/h > ddd/h d m / dd
16 d W< W< h ^ d ^ W< ^ D, de, d W< D ^ & /h d ^ d e dd t ddd/h d edl ddd/h >de ed dddl dd/h > t h d de de de, m d de /, dd
17 dd de ed W, de ed d K t ddd /h d ddl de ddd/h > d, W< D mddd/h > e e de dd / ddd /h > d de
18 d W< t W< d W<, E t t D ^, Z d E d / D ^ Z W : W D de
19 de Z d t ' D,: D> Dd :, dddde d dde dde d Z> :Z> ^ Zd W / ^ / D deed ed e eed e d : E d > > Z deed e eede d W Z, ^W : > dddde dde dde d W > d Z Z d h, > ^ Z > > : K ddde eded edee e ^ > ' Z s< / & W ed ddee d ddddde e ^ t> ^ :' K ' dddd dde d e ^ t ^ E ^ D K d dd ddde dd e s/ ^ ^ h ^ W< W EKEDD >> :W, K ddde de d dde dde d t, W Z < ':> W' ddd ddde dd D ^ ^ & K Z d > ' d ddee e dedede D > Z & / >> W ed ddde dde d eee e < ^ < ^<, >,W Y d z D DZ >> W ddde de d dee d Z D D, ddde ed d E ' h ^ t W :, deee ee d eed eed de Z D s > > > K ddd dee ded de ^ /D s >D W Z, ddde dd dee ded
20 de de > t : : Z /W ^ ^,: : K deed e deed deee de W Z / <, : W d ddde d dedede ^ W Z <, : :, ' W W, K d & ddde d dded, ' D,: > < t ', : :, dddde d dde d ^ W Z <, : :, ' W W, K d & ddde d dded < : W ^, ^ < Ed W W ddde d ee ed < ^, / : D W :, dddd eed eed s >D < // d / & t > > W ddde ed d dde d de d t, W Z, t: > < : ^ /D E W dded d dde ded de :, E,' d W< W ddd ddde de, E, W deee d dde d de t W DzD < W Z ddde e dded dded ^ / s t, : dded d de d W, > W 'Z t > W K ' ^ ddee d dede de W ' s s & d > /KW >>ee, ddee d dee ded : t ' D : deee e dddd s >D < // W ddde ed d dde d D Z ^ E :D deee dde de ddee de, ' ^ ': t, ' :W deee ed d ed ee de & dede E d d d
21 de de W W : W / / dd ddde ddddddde ded d t, W Z ' <, d W', ddee dede de Z D D, ddde ed d dd
22 d>^ d d W W d dd D e Z d e de e ' l D ed el & de de dl t D d Z e ee d ^ d D d ed Z d d dd l l ^l dd
23 d d W< ^ l d edd eee dl E de d el W dd ddl dd dee ee dl ^ D dd Z d dd ^ t d de d dl d e d dl de ded dl ed ded de el ed d e dl ^ dd
24 d d W W W Z^ l edl/ edl/ ^ l D edl/ edl/ > > ed d dd ddl d dd d dd d dd d dd d dd s > ed d d ddl d e d e d d d d e e Y > ed d dd ddl d dd d de d dd d dd d dd s > ed d e ddl d e d d d e d e d d > d d d dl d de d dd d dd d dd d dd //s> l dd dd dd d d d dd de dd /Ks l dd de e de d e dd e de Z d de e dl d dd d ed e d d de d dd d ed /h > > s Y s > d //s /Ks dd
25 &/'hz^ & d & d /h > d d dd & d ' & d' W W / l & d s W & dw s d edl d dl edl edl & d ^ d & ddl edl de d d d d d ddd/h > & d mddd/h > de & dz /h d /h d d mddd /h > de d ddl edl ddl edl mddd/h > & e ^ mdd/h > de & ez /h e /h d e mdd/h > de d ddl edl ddl edl mdd/h > dd
26
27
28
29
30
31
32 Supplement Pharmacokinetic analysis Time profiles of Erwinia asparaginase concentrations were analyzed using the nonlinear mixed effects modeling approach implemented in NONMEM (version 7.2; Icon Development Solutions, Ellicott City, Maryland, USA). Additionally Pirana (version 2.7.1, for the model environment Pirana, Pirana Software & Consulting BV, The Netherlands) 1, Xpose (version 4.4.1, Nicholas Jonsson and Mats Karlsson, Uppsala, Sweden) 2 and Perl speaks NONMEM (PsN) (version 4.2.0, Uppsala, Sweden) 3 were used. All Erwinia asparaginase concentrations were log transformed prior to analysis. First order conditional estimates with interaction (FOCE+I) was used as method of analysis throughout the model building procedure. The data was initially fitted to a one-compartment linear model without an absorption compartment as the drug was administered intravenously. More complex models were evaluated; improvement of the fit of the model was evaluated by the precision of the estimated PK parameters, the change in the objective function values (OFV), goodness-of-fit plots (GOF) and visual predictive checks (VPC). A 3.84 point decrease in OFV for one degree of freedom was considered a significant improvement with a p-value of <0.05. The data was obtained in a pediatric population, hence PK parameters were allometrically scaled to adequately describe the parameters across a wide range of body weights. For allometric scaling standard fixed exponent values of 0.75 for the flow dependent physiologic process parameters clearance (CL) and intercompartmental clearance (Q), and 1 for the volume related parameters apparent volume of distribution of the central compartment (V c) and peripheral compartment (V p) were used. 4 6 Inter-patient and inter-occasion variability in clearances and volumes of distribution were characterized with exponential models. An occasion was defined as one month of treatment due to
33 the limited number of samples per occasion. For example, clearance in the i th individual at the j th occasion was estimated using equation 1: Eq.1 CL i,j = CL pop *(WT/70) 0.75 * exp (η i + κ j) Where CL pop (= Θ CL) is the typical population value for clearance in a patient with a standardized body weight of 70 kg and η i and K j represents the random effect accounting for inter-individual deviation from the typical population value (IIV) and typical individual values (IOV) respectively. η i and k j are assumed to be symmetrically distributed with a mean of 0 and estimated variance of ω 2 and π 2, respectively. An additive error model was used to describe the residual error in plasma concentrations. After the finalization of the structural model, covariate models were built by a stepwise forward inclusion procedure. Continuous covariates were centered at the median and included in the model as described in equation 2. Categorical covariates were included in the model as described in equation 3: Eq.2 CL i,j = [CL pop*(cov/median COV) Θcov * (WT/70) 0.75 ]* exp (η i + κ j) Eq.3 CL i,j = [CL pop*( Θ cat) FLAG * (WT/70) 0.75 ]* exp (η i + κ j) Where COV is the continuous covariate, Θ cov is the estimated exponent parameter of the continuous covariate. Θ cat is the estimated fraction parameter of the categorical covariate. FLAG is either 1 (covariate present) or 0 (not present). Other parameters are described in equation 1. Covariates were included one at the time. The covariate with the greatest reduction in OFV was added to the base model. This was iterated over all the covariates until no statistically significant decrease in
34 OFV occurred. The available covariates were: weight, age, height, body surface area (BSA), sex, treatment protocol (ALL-10 and ALL-11) and treatment center. Dose interval was evaluated as covariate for patient on thrice weekly or every other day Erwinia asparaginase versus patients who switched to twice weekly Erwinia asparaginase. For the internal validation of the model a non-parametric bootstrap procedures (n=1000) was performed and prediction corrected visual predictive checks (VPC) were obtained. The final model including covariates was used to perform Monte Carlo simulations (n=5000) for doses ranging from 100 to 2000 IU/kg (per 100 IU/kg steps) for patients weighing 10 to 100 kg (per 10 kg steps). Conversion of IU/kg dose to IU/m 2 : Eq.4 Dose (IU/m 2 ) = (dose (IU/kg)*body weight (kg))/bsa (m 2 ) BSA is the body surface area used in this formula is the BSA calculated from weight alone as described by Sharkey et al. 7 Dose interval correction Doses are adjusted according to asparaginase levels. Patients with high levels can switch to twice weekly administration. These patients have samples in the hour timeframe. Figure 1 shows the pcvpc with the covariate interval (patients with twice weekly dosing versus thrice weekly). This improves the median predictions especially concerning the hour timeframe. However variability is under predicted.
35 References 1. Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed Jan;101(1): Jonsson EN, Karlsson MO. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed Jan;58(1): Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed Sep;79(3): Anderson BJ, Holford NHG. Tips and traps analyzing pediatric PK data. Paediatr Anaesth Mar;21(3): Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet May;30(5): Wang C, Peeters MYM, Allegaert K, et al. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res. Springer; 2012 Jun 1;29(6): Sharkey I, Boddy A V, Wallace H, et al. Body surface area estimation in children using weight alone: application in paediatric oncology. Br J Cancer. Nature Publishing Group; 2001 Jul 6;85(1):23 8.
36 Figure 1: Asparaginase concentration vs time after dose (interval adjustment) Figure 1 Prediction corrected Visual prediction plot of observed log asparaginase levels versus time after dose (hours) of the final model with covariate dose interval. The red solid line indicates the median observed levels and the surrounding opaque red area the simulation based 95% interval for the median. The red dashed lines indicates the observed 5% and 95% percentiles and the surrounding opaque blue areas show the simulated 95% confidence intervals for the corresponding predicted percentiles.
d ^dzd K DZ/ '^ ^ '^ K '^ / '^ / DZ/ W / ^ d Eled ^ d Eldd dd d e t d d e de ^ '^ de ddl '^
DZ/, ^ : ' t ' D ^ E > E / D, ^ : ' W > E/D, E/, dd Z d dde Dddeed ddee ddd ddd dede E /, D d ^dzd K DZ/ '^ ^ '^ K '^ / '^ / DZ/ W / ^ d Eled ^ d Eldd dd d e t d d e de ^ '^ de ddl '^ d d '^ t '^ d /EdZKhd/KE
More informationh D t del d ddl ddl el del d < d
> Z Z d : d h D d, Z d d / d W < ^ d d d ' e W E e > ^ d d / & d e ^ < e Z d e & D d e h s d : ^ d e d ' D ' h ' ' ' d / / ' h ^ ^ ' d / / ' & ' h D ' ' ' d W ' h ' ' ' d ' D ' ' > ' h ' ' ' e D /' /EZh
More informationCopyright 2010 by the American Society for Pharmacology and Experimental Therapeutics.
DMD This Fast article Forward. has not been Published copyedited and on formatted. July 15, The 2010 final as version doi:10.1124/dmd.110.033936 may differ from this version. / & W W, / > W > Z z d >,
More informationPublished Ahead of Print on August 16, 2018, as doi: /haematol Copyright 2018 Ferrata Storti Foundation.
Published Ahead of Print on August 16, 2018, as doi:10.3324/haematol.2018.196121. Copyright 2018 Ferrata Storti Foundation. Computed tomography pulmonary angiography versus ventilation-perfusion lung scan
More informationMolecular Pharmacology Fast Forward. Published on June 29, 2016 as DOI: /mol This article has not been copyedited and formatted.
, W D E / & h E D D D Z W, W D / & h dddd h D D d dddddedddede dddddeddddee & dddddedddede d d d & d dee d eddd Z dde DW d d d W/ d d e e d d d d d, d /^ d db d db E< E l
More informationPublished Ahead of Print on July 9, 2015, as doi: /haematol Copyright 2015 Ferrata Storti Foundation.
Published Ahead of Print on July 9, 2015, as doi:10.3324/haematol.2015.125864. Copyright 2015 Ferrata Storti Foundation. Impact of prior treatment and depth of response on survival in MM-003, a randomized
More informationMediastinal Grey Zone Lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the LYSA
Published Ahead of Print on October 6, 2016, as doi:10.3324/haematol.2016.152256. Copyright 2016 Ferrata Storti Foundation. Mediastinal Grey Zone Lymphoma: clinico-pathological characteristics and outcomes
More informationW W D D ddd ^ D,, Z > tdddee d lddddddededdedd ' d W d
dd WZde de& WZddd ' d d d E < d K d ' ^ d Z d Z E ' d d >, d K D d K d Z E d > E d D e E ^ e W D D d d ^ D / > > h < d W D / W W E < > > h < d / / ^ > h < d Y ^ D ^ / E h > > h < d / > > h < e D ^ E h
More informationPublished Ahead of Print on August 1, 2014, as doi: /haematol Copyright 2014 Ferrata Storti Foundation.
Published Ahead of Print on August 1, 2014, as doi:10.3324/haematol.2014.106096. Copyright 2014 Ferrata Storti Foundation. Outcome of Aplastic Anemia in adolescence. A survey of the Severe Aplastic Anemia
More informationBlood First Edition Paper, prepublished online March 7, 2018; DOI /blood
Blood First Edition Paper, prepublished online March 7, 2018; DOI 10.1182/blood-2017-12-822817 ^ E& /s>> > >zdw,k/ekw>^/, Dzee ee D Z ^ d W D : d Z t d D, s d D : d ^ & ^ d :,, s d Z d t < d D : < d D
More informationOverview of the Accountancy Profession in China
2016I1-024 Overview of the Accountancy Profession in China (Released by CICPA, Updated on January 21, 2016) /K D d // / W d ///^ d d d /s^ / ^ e s^ W D & e s/^ E ^ e s///d^ W e s///y W dd /y/ dd y/ dd
More informationInflammation and organ failure severely affect midazolam clearance in critically ill children
Online Data Supplement Inflammation and organ failure severely affect midazolam clearance in critically ill children Nienke J. Vet, MD 1,2 * Janneke M. Brussee, MSc 3* Matthijs de Hoog, MD, PhD 1,2 Miriam
More informationDesmopressin in moderate hemophilia A patients: a treatment worth considering
Published Ahead of Print on January 5, 2018, as doi:10.3324/haematol.2017.180059. Copyright 2018 Ferrata Storti Foundation. Desmopressin in moderate hemophilia A patients: a treatment worth considering
More information3 Results. Part I. 3.1 Base/primary model
3 Results Part I 3.1 Base/primary model For the development of the base/primary population model the development dataset (for data details see Table 5 and sections 2.1 and 2.2), which included 1256 serum
More informationPublished Ahead of Print on May 24, 2018, as doi: /haematol Copyright 2018 Ferrata Storti Foundation.
Published Ahead of Print on May 24, 2018, as doi:10.3324/haematol.2018.193151. Copyright 2018 Ferrata Storti Foundation. Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia
More informationR-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL)
R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL) Thierry Lamy, Gandhi Damaj, Pierre Soubeyran, Emmanuel Gyan, Guillaume Cartron, Krimo Bouabdallah,
More informationMolecular Pharmacology Fast Forward. Published on January 6, 2017 as DOI: /mol This article has not been copyedited and formatted.
d/d>w' d zddd & Z d ' W d : z t Z ' :, & D W, > > d/w/ D^ Z / Dh^ d W zt Z' d D^ Z / Dh^ ' d: :, &D >> d/w/ D ^ ' W, d ZhEE/E'd/d>W' Z W D^ Z / ddd d Dddedd ld eee ded dddd d de E d E e E de ddd / edd
More informationhzkwekdd/^^/ke /ZdKZd 'EZ> >/Ddd/KE / D ' e h d^ dddd, & & dd dddd d
hzkwekdd/^^/ke /ZdKZd'EZ> >/D/KE /D 'e hd^,& & d d d / d dd ^' d dd /D' d dd h' d dd d dd ^ d de W d d, e dd,d^ e dd,d^d^ dd,d^d^ d, dd K dd,d^ de dd,d^ dd D dd D de d ^d: dd dd d ^ dd, dd, d d / dd ^'
More informationCan we reduce health inequalities? An analysis of the English strategy ( )
Can we reduce health inequalities? An analysis of the English strategy (1997-2010) Johan P Mackenbach To cite this version: Johan P Mackenbach. Can we reduce health inequalities? An analysis of the English
More informationPublished Ahead of Print on May 10, 2018, as doi: /haematol Copyright 2018 Ferrata Storti Foundation.
Published Ahead of Print on May 10, 2018, as doi:10.3324/haematol.2017.186569. Copyright 2018 Ferrata Storti Foundation. Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years)
More informationHistorical review of glasses used for parenteral packaging
Downloaded from on November 13, 2018 Historical review of glasses used for parenteral packaging Robert A Schaut and W. Porter Weeks PDA Journal of Pharmaceutical Science and Technology 2017, Access the
More informationDescription of UseCase models in MDL
Description of UseCase models in MDL A set of UseCases (UCs) has been prepared to illustrate how different modelling features can be implemented in the Model Description Language or MDL. These UseCases
More informationPublished Ahead of Print on September 29, 2017, as doi: /haematol Copyright 2017 Ferrata Storti Foundation.
Published Ahead of Print on September 29, 2017, as doi:10.3324/haematol.2017.174441. Copyright 2017 Ferrata Storti Foundation. Mixed phenotype acute leukemia: Outcomes with allogeneic stem cell transplantation,
More informationPD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict survival in primary testicular lymphoma
Published Ahead of Print on July 19, 2018, as doi:10.3324/haematol.2018.197194. Copyright 2018 Ferrata Storti Foundation. PD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict
More informationCorrection of the likelihood function as an alternative for imputing missing covariates. Wojciech Krzyzanski and An Vermeulen PAGE 2017 Budapest
Correction of the likelihood function as an alternative for imputing missing covariates Wojciech Krzyzanski and An Vermeulen PAGE 2017 Budapest 1 Covariates in Population PKPD Analysis Covariates are defined
More informationPublished Ahead of Print on June 10, 2013, as doi: /haematol Copyright 2013 Ferrata Storti Foundation.
Published Ahead of Print on June 10, 2013, as doi:10.3324/haematol.2013.088377. Copyright 2013 Ferrata Storti Foundation. Early Release Paper First line treatment with rituximab- Hyper-CVAD alternating
More informationHIF-1 can act as a tumor suppressor gene in murine Acute Myeloid Leukemia.
HIF-1 can act as a tumor suppressor gene in murine Acute Myeloid Leukemia. Velasco, Talia; Hyrenius Wittsten, Axel; Rehn, Matilda; Bryder, David; Cammenga, Jörg Published in: Blood DOI: 1.1182/blood-14-4-56765
More informationPrinciples of Covariate Modelling
1 Principles of Covariate Modelling Nick Holford Dept of Pharmacology & Clinical Pharmacology University of Auckland New Zealand 2 What is a Covariate? A covariate is any variable that is specific to an
More informationResearch Article. Multiple Imputation of Missing Covariates in NONMEM and Evaluation of the Method s Sensitivity to η-shrinkage
The AAPS Journal, Vol. 15, No. 4, October 2013 ( # 2013) DOI: 10.1208/s12248-013-9508-0 Research Article Multiple Imputation of Missing Covariates in NONMEM and Evaluation of the Method s Sensitivity to
More informationChallenges in modelling the pharmacokinetics of isoniazid in South African tuberculosis patients
PAGE 2005 Pamplona, Spain Challenges in modelling the pharmacokinetics of isoniazid in South African tuberculosis patients Justin J Wilkins 1, Grant Langdon 1, Helen McIlleron 1, Goonaseelan Pillai 2,
More informationBody Size is the most important quantitative determinant of drug dose
1 2 Babies, Children, Adults Are All One Species Integrated Rational Dosing Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland Body Size is the most important quantitative determinant
More informationF. Combes (1,2,3) S. Retout (2), N. Frey (2) and F. Mentré (1) PODE 2012
Prediction of shrinkage of individual parameters using the Bayesian information matrix in nonlinear mixed-effect models with application in pharmacokinetics F. Combes (1,2,3) S. Retout (2), N. Frey (2)
More informationTHE EURES WORLD. Handbook
THE EURES WORLD Handbook 01. EURES: general information hz^ deed / W ^ W^ D ^ h E / > ^ hz^ dd hz^ History and objectives, W hz^ deed W ^ W^ D ^ h E / > ^ hz^ d / W^ d h K h d hz^ hz^ d d hz^ d hz^ d >
More informationCurrent approaches to covariate modeling
Current approaches to covariate modeling Douglas J. Eleveld, Ph.D., Assistant Professor University of Groningen, University Medical Center Groningen, Department of Anesthesiology, Groningen, The Netherlands
More informationQuestion&Answers. 9 November 2011
hzkwekdd/^^/ke /ZdKZd 'EZ> >/Ddd/KE / D Question&Answers h d^ dddd 9 November 2011 This document has been developed building on the frequently asked questions to the Helpdesk for the Member States Competent
More informationModelling a complex input process in a population pharmacokinetic analysis: example of mavoglurant oral absorption in healthy subjects
Modelling a complex input process in a population pharmacokinetic analysis: example of mavoglurant oral absorption in healthy subjects Thierry Wendling Manchester Pharmacy School Novartis Institutes for
More informationThe general concept of pharmacokinetics
The general concept of pharmacokinetics Hartmut Derendorf, PhD University of Florida Pharmacokinetics the time course of drug and metabolite concentrations in the body Pharmacokinetics helps to optimize
More informationEstimation and Model Selection in Mixed Effects Models Part I. Adeline Samson 1
Estimation and Model Selection in Mixed Effects Models Part I Adeline Samson 1 1 University Paris Descartes Summer school 2009 - Lipari, Italy These slides are based on Marc Lavielle s slides Outline 1
More informationA Novel Screening Method Using Score Test for Efficient Covariate Selection in Population Pharmacokinetic Analysis
A Novel Screening Method Using Score Test for Efficient Covariate Selection in Population Pharmacokinetic Analysis Yixuan Zou 1, Chee M. Ng 1 1 College of Pharmacy, University of Kentucky, Lexington, KY
More informationSafety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study
Published Ahead of Print on May 17, 2018, as doi:10.3324/haematol.2017.171249. Copyright 2018 Ferrata Storti Foundation. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia
More informationCatalytically inactive Gla-domainless factor Xa binds to TFPI and restores ex vivo coagulation in hemophilia plasma
Published Ahead of Print on October 5, 2017, as doi:10.3324/haematol.2017.174037. Copyright 2017 Ferrata Storti Foundation. Catalytically inactive Gla-domainless factor Xa binds to TFPI and restores ex
More information! "! # $ % '()*% +,-'"& %.% /)01( ).%.) %')1/ ) %'%
! "! # $ % "& '()*% +,-'"& %.% /)01( ).%.) %')1/ ) %'% Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Pharmacokinetics and Drug Therapy presented at Uppsala University in
More informationPopulation Pharmacokinetics in Support of Analgesics and Anaesthetics Studies in
Pyry Välitalo Population Pharmacokinetics in Support of Analgesics and Anaesthetics Studies in Special Populations Publications of the University of Eastern Finland Dissertations in Health Sciences 7.4
More informationCopyright 2012 by the American Society for Pharmacology and Experimental Therapeutics.
DMD Fast This Forwar. article has not Publishe been copyeite on an February formatte. 16, The final 2012 version as oi:10.1124/m.111.042994 may iffer from this version. D, D:, z > z < ^ < ^ < :, ' < ^&
More informationSET-Plan - SOLAR THERMAL ELECTRICITY EUROPEAN INDUSTRIAL INITIATIVE (STE-EII)
SET-Plan - SOLAR THERMAL ELECTRICITY EUROPEAN INDUSTRIAL INITIATIVE (STE-EII) IMPLEMENTATION PLAN 2013-2015 dd dddd ^//d d ^ / / ^d / dddd dddd /Ey /Ey d '>K^^Zz d /EdZKhd/KE e /,/sded^/ez ^/Ed,'/EE/E'K&d,^d
More informationLate thyroid complications in childhood acute leukemia survivors. An L.E.A. study
Published Ahead of Print on March 11, 2016, as doi:10.3324/haematol.2015.140053. Copyright 2016 Ferrata Storti Foundation. Late thyroid complications in childhood acute leukemia survivors. An L.E.A. study
More informationRobust design in model-based analysis of longitudinal clinical data
Robust design in model-based analysis of longitudinal clinical data Giulia Lestini, Sebastian Ueckert, France Mentré IAME UMR 1137, INSERM, University Paris Diderot, France PODE, June 0 016 Context Optimal
More informationTreatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the EXELS study
Published Ahead of Print on October 27, 2017, as doi:10.3324/haematol.2017.174672. Copyright 2017 Ferrata Storti Foundation. Treatment of essential thrombocythemia in Europe: a prospective long-term observational
More informationConfidence and Prediction Intervals for Pharmacometric Models
Citation: CPT Pharmacometrics Syst. Pharmacol. (218) 7, 36 373; VC 218 ASCPT All rights reserved doi:1.12/psp4.12286 TUTORIAL Confidence and Prediction Intervals for Pharmacometric Models Anne K ummel
More informationA comparison of estimation methods in nonlinear mixed effects models using a blind analysis
A comparison of estimation methods in nonlinear mixed effects models using a blind analysis Pascal Girard, PhD EA 3738 CTO, INSERM, University Claude Bernard Lyon I, Lyon France Mentré, PhD, MD Dept Biostatistics,
More informationNonlinear Mixed Effects Models
Nonlinear Mixed Effects Modeling Department of Mathematics Center for Research in Scientific Computation Center for Quantitative Sciences in Biomedicine North Carolina State University July 31, 216 Introduction
More informationand ALiTO SOLO LOWELL, MICHIGAN, THURSDAY, AUGUST 9, 1928 First Results of the 1928 Nationwide Presidential Poll
E E XXX E Y! D 22 5 Q G Y G Y D G G q - YEE 24-? G Y E x - E Q- E 7// < D D D G E G D - 2 ; - j E ; (z ; 4 2 z 5 q z: G $7 z: $5 z: $3 E G DY G 9 928 54 Y! 8! GEG : : ; j: D - DY DY G z D zz!!!-! G E DDED
More informationCovariate Model Building in Nonlinear Mixed Effects Models
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 59 Covariate Model uilding in Nonlinear Mixed Effects Models JKO RIING CT UNIVERSITTIS UPSLIENSIS UPPSL 2007 ISSN 1651-6192
More informationPhase 3 results for vosaroxin/cytarabine in the subset of patients 60 years old with refractory/early relapsed acute myeloid leukemia
Publishe Ahea of Print on May 24, 2018, as oi:10.3324/haematol.2018.191361. Copyright 2018 Ferrata Storti Founation. Phase 3 results for vosaroxin/cytarabine in the subset of patients 60 years ol with
More informationPhase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma
Publishe Ahea of Print on February 20, 2015, as oi:10.3324/haematol.2014.119735. Copyright 2015 Ferrata Storti Founation. Phase I/II Stuy of the Combination of Panobinostat an Carfilzomib in Patients with
More informationInfluence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research
British Journal of Clinical Pharmacology DOI:1.1111/bcp.13 Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research Chiara Piana, 1 Meindert Danhof
More informationIntegration of SAS and NONMEM for Automation of Population Pharmacokinetic/Pharmacodynamic Modeling on UNIX systems
Integration of SAS and NONMEM for Automation of Population Pharmacokinetic/Pharmacodynamic Modeling on UNIX systems Alan J Xiao, Cognigen Corporation, Buffalo NY Jill B Fiedler-Kelly, Cognigen Corporation,
More informationPHA 4123 First Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 4123 First Exam Fall 1998 On my honor, I have neither given nor received unauthorized aid in doing this assignment. TYPED KEY Name Question 1. / pts 2. /2 pts 3. / pts 4. / pts. / pts 6. /10 pts 7.
More informationLabrador Island Transmission Link
Labrador Island Transmission Link Wetlands Inventory and Classification W Nalcor Energy Hydro Place, 500 Columbus Drive P.O. Box 12800 St. John s, Newfoundland and Labrador Canada A1B 0C9 tdkdzddedt K
More informationCase Study in the Use of Bayesian Hierarchical Modeling and Simulation for Design and Analysis of a Clinical Trial
Case Study in the Use of Bayesian Hierarchical Modeling and Simulation for Design and Analysis of a Clinical Trial William R. Gillespie Pharsight Corporation Cary, North Carolina, USA PAGE 2003 Verona,
More informationTHE IMPORTANCE OF THE SIMULATION EXPECTATION AS A GOODNESS OF FIT DIAGNOSTIC FOR CATEGORICAL POPULATION PHARMACODYNAMIC MODELS
THE IMPORTANCE OF THE SIMULATION EXPECTATION AS A GOODNESS OF FIT DIAGNOSTIC FOR CATEGORICAL POPULATION PHARMACODYNAMIC MODELS Marc R. Gastonguay, Jeffrey T. Hane Metrum Research Group LLC, Avon, CT 06001
More informationAn Approach for Identifiability of Population Pharmacokinetic-Pharmacodynamic Models
An Approach for Identifiability of Population Pharmacokinetic-Pharmacodynamic Models Vittal Shivva 1 * Julia Korell 12 Ian Tucker 1 Stephen Duffull 1 1 School of Pharmacy University of Otago Dunedin New
More informationMETHODS FOR POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS
METHODS FOR POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS Emily Anne Colby A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements
More informationAccurate Maximum Likelihood Estimation for Parametric Population Analysis. Bob Leary UCSD/SDSC and LAPK, USC School of Medicine
Accurate Maximum Likelihood Estimation for Parametric Population Analysis Bob Leary UCSD/SDSC and LAPK, USC School of Medicine Why use parametric maximum likelihood estimators? Consistency: θˆ θ as N ML
More informationMulticompartment Pharmacokinetic Models. Objectives. Multicompartment Models. 26 July Chapter 30 1
Multicompartment Pharmacokinetic Models Objectives To draw schemes and write differential equations for multicompartment models To recognize and use integrated equations to calculate dosage regimens To
More informationBasic Concepts in Population Modeling, Simulation, and Model-Based Drug Development Part 2: Introduction to Pharmacokinetic Modeling Methods
Tutorial Citation: CPT: Pharmacometrics & Systems Pharmacology (3), e38; doi:.38/psp.3.4 3 ASCPT All rights reserved 63-836/ www.nature.com/psp Basic Concepts in Population Modeling, Simulation, and Model-Based
More informationHow Critical is the Duration of the Sampling Scheme for the Determination of Half-Life, Characterization of Exposure and Assessment of Bioequivalence?
How Critical is the Duration of the Sampling Scheme for the Determination of Half-Life, Characterization of Exposure and Assessment of Bioequivalence? Philippe Colucci 1,2 ; Jacques Turgeon 1,3 ; and Murray
More informationDosing In NONMEM Data Sets an Enigma
PharmaSUG 2018 - Paper BB-02 ABSTRACT Dosing In NONMEM Data Sets an Enigma Sree Harsha Sreerama Reddy, Certara, Clarksburg, MD; Vishak Subramoney, Certara, Toronto, ON, Canada; Dosing data plays an integral
More informationPharmacometrics : Nonlinear mixed effect models in Statistics. Department of Statistics Ewha Womans University Eun-Kyung Lee
Pharmacometrics : Nonlinear mixed effect models in Statistics Department of Statistics Ewha Womans University Eun-Kyung Lee 1 Clinical Trials Preclinical trial: animal study Phase I trial: First in human,
More informationPublished Ahead of Print on April 19, 2018, as doi: /haematol Copyright 2018 Ferrata Storti Foundation.
Published Ahead of Print on April 19, 2018, as doi:10.3324/haematol.2018.189837. Copyright 2018 Ferrata Storti Foundation. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic
More informationDESIGN EVALUATION AND OPTIMISATION IN CROSSOVER PHARMACOKINETIC STUDIES ANALYSED BY NONLINEAR MIXED EFFECTS MODELS
DESIGN EVALUATION AND OPTIMISATION IN CROSSOVER PHARMACOKINETIC STUDIES ANALYSED BY NONLINEAR MIXED EFFECTS MODELS Thu Thuy Nguyen, Caroline Bazzoli, France Mentré UMR 738 INSERM - University Paris Diderot,
More informationTMDD Model Translated from NONMEM (NM- TRAN) to Phoenix NLME (PML)
TMDD Model Translated from NONMEM (NM- TRAN) to Phoenix NLME (PML) Phoenix Modeling Language School March 22, 2018 Loan Pham, Ph.D. Senior Pharmacokinetic Scientist Camargo Pharmaceutical Services 9825
More informationPK-QT analysis of bedaquiline : Bedaquiline appears to antagonize its main metabolite s QTcF interval prolonging effect
PK-QT analysis of bedaquiline : Bedaquiline appears to antagonize its main metabolite s QTcF interval prolonging effect Lénaïg Tanneau 1, Elin Svensson 1,2, Stefaan Rossenu 3, Mats Karlsson 1 1 Department
More informationFitting PK Models with SAS NLMIXED Procedure Halimu Haridona, PPD Inc., Beijing
PharmaSUG China 1 st Conference, 2012 Fitting PK Models with SAS NLMIXED Procedure Halimu Haridona, PPD Inc., Beijing ABSTRACT Pharmacokinetic (PK) models are important for new drug development. Statistical
More informationPopulation Approach. Pharmacokinetics. Analysis Approaches. Describing The Signal and the Noise
1 Population Approach Describing The Signal and the Noise 2 Pharmacometrics Science Pharmacology Models Pharmacokinetics Pharmacodynamics Experiment Dose Concentration Effect 3 Analysis Approaches ANOVA
More informationHandling parameter constraints in complex/mechanistic population pharmacokinetic models
Handling parameter constraints in complex/mechanistic population pharmacokinetic models An application of the multivariate logistic-normal distribution Nikolaos Tsamandouras Centre for Applied Pharmacokinetic
More informationOn drug transport after intravenous administration
On drug transport after intravenous administration S.Piekarski (1), M.Rewekant (2) Institute of Fundamental Technological Research Polish Academy of Sciences (1), Medical University of Warsaw, Poland Abstract
More informationEstimating terminal half life by non-compartmental methods with some data below the limit of quantification
Paper SP08 Estimating terminal half life by non-compartmental methods with some data below the limit of quantification Jochen Müller-Cohrs, CSL Behring, Marburg, Germany ABSTRACT In pharmacokinetic studies
More informationThe reaction whose rate constant we are to find is the forward reaction in the following equilibrium. NH + 4 (aq) + OH (aq) K b.
THE RATES OF CHEMICAL REACTIONS 425 E22.3a The reaction for which pk a is 9.25 is NH + 4 aq + H 2Ol NH 3 aq + H 3 O + aq. The reaction whose rate constant we are to find is the forward reaction in the
More informationNonlinear mixed-effects models using Stata
Nonlinear mixed-effects models using Stata Yulia Marchenko Executive Director of Statistics StataCorp LP 2017 German Stata Users Group meeting Yulia Marchenko (StataCorp) 1 / 48 Outline What is NLMEM?
More informationAssessing the Effect of Prior Distribution Assumption on the Variance Parameters in Evaluating Bioequivalence Trials
Georgia State University ScholarWorks @ Georgia State University Mathematics Theses Department of Mathematics and Statistics 8--006 Assessing the Effect of Prior Distribution Assumption on the Variance
More informationd d / d d d ^ ' d d d /D' d d d h ' d d d d d d ^ d d ^ e d d e d d e d d d d d d d W d d, de d d & de d d W d d d d d W d d & d e d /D e de e d de e
hzkwekdd/^^/ke /ZdKZd 'EZ> >/D/KE / D ' d h d^ ' & d d d / d d d ^ ' d d d /D' d d d h ' d d d d d d ^ d d ^ e d d e d d e d d d d d d d W d d, de d d & de d d W d d d d d W d d & d e d /D e de e d de
More informationON THE CONSEQUENCES OF MISSPECIFING ASSUMPTIONS CONCERNING RESIDUALS DISTRIBUTION IN A REPEATED MEASURES AND NONLINEAR MIXED MODELLING CONTEXT
ON THE CONSEQUENCES OF MISSPECIFING ASSUMPTIONS CONCERNING RESIDUALS DISTRIBUTION IN A REPEATED MEASURES AND NONLINEAR MIXED MODELLING CONTEXT Rachid el Halimi and Jordi Ocaña Departament d Estadística
More informationTorsten: Stan functions for pharmacometrics applications
Torsten: Stan functions for pharmacometrics applications Bill Gillespie Metrum Research Group Stan for Pharmacometrics Paris, France 24 July 2018 c 2018 Torsten: Stan functions for PMX 24 July 2018 1 /
More informationNoncompartmental vs. Compartmental Approaches to Pharmacokinetic Data Analysis Paolo Vicini, Ph.D. Pfizer Global Research and Development David M.
Noncompartmental vs. Compartmental Approaches to Pharmacokinetic Data Analysis Paolo Vicini, Ph.D. Pfizer Global Research and Development David M. Foster., Ph.D. University of Washington October 28, 2010
More informationBeka 2 Cpt: Two Compartment Model - Loading Dose And Maintenance Infusion
MEDSCI 719 Pharmacometrics Beka 2 Cpt: Two Compartment Model - Loading Dose And Maintenance Infusion Objective 1. To observe the time course of drug concentration in the central and peripheral compartments
More informationNonlinear pharmacokinetics
5 Nonlinear pharmacokinetics 5 Introduction 33 5 Capacity-limited metabolism 35 53 Estimation of Michaelis Menten parameters(v max andk m ) 37 55 Time to reach a given fraction of steady state 56 Example:
More informationImplementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes
Publishe Ahea of Print on September 22, 2016, as oi:10.3324/haematol.2016.147843. Copyright 2016 Ferrata Storti Founation. Implementation of erythroi lineage analysis by flow cytometry in iagnostic moels
More informationNoncompartmental vs. Compartmental Approaches to Pharmacokinetic Data Analysis Paolo Vicini, Ph.D. Pfizer Global Research and Development David M.
Noncompartmental vs. Compartmental Approaches to Pharmacokinetic Data Analysis Paolo Vicini, Ph.D. Pfizer Global Research and Development David M. Foster., Ph.D. University of Washington October 18, 2012
More informationNon-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations
Computer Methods and Programs in Biomedicine () 76, 31 Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations Christoffer W.Tornøe a, *, Henrik Agersø a,
More informationBayesian pharmacometric modeling with BUGS, NONMEM and Stan
Bayesian pharmacometric modeling with BUGS, NONMEM and Stan Bill Gillespie Metrum Research Group 22 May 215 c 215 Metrum Research Group Bayesian pharmacometric tools 22 May 215 1 / 52 Introduction Bayesian
More informationEfficient multivariate normal distribution calculations in Stata
Supervisor: Adrian Mander MRC Biostatistics Unit 2015 UK Stata Users Group Meeting 10/09/15 1/21 Why and what? Why do we need to be able to work with the Multivariate Normal Distribution? The normal distribution
More informationEvaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixedeffects
Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics Hoai-Thu Thai, France Mentré, Nick Holford,
More information1. Describing patient variability, 2. Minimizing patient variability, 3. Describing and Minimizing Intraindividual
1. Describing patient variability, 2. Minimizing patient variability, 3. Describing and Minimizing Intraindividual Variability. 4. Improving the reporting of lab assay results. Roger Jelliffe MD, Alan
More information535.37(075.8) : /, ISBN (075.8) ISBN , 2008, 2008
.. 2008 535.37(075.8) 22.34573 66.. 66 : /... : -, 2008. 131. ISBN 5-98298-312-8 -,, -,,, -, -., 200203 «-».,,, -. 535.37(075.8) 22.34573 -,.. ISBN 5-98298-312-8.., 2008, 2008., 2008 2 , -. :,, - ;,, ;
More informationMAT 17A - UHP - DISCUSSION #10 December 1, 2015
MAT 17A - UHP - DISCUSSION #10 December 1, 2015 PROBLEM 1. Linear recursion equations Consider the linear recursion (finite difference) equation x j+1 = L x j = a x j + b, x 0 (1), where a and b are: (i)
More information1 Introduction. 2 Example
Statistics: Multilevel modelling Richard Buxton. 2008. Introduction Multilevel modelling is an approach that can be used to handle clustered or grouped data. Suppose we are trying to discover some of the
More informationAnalytics Software. Beyond deterministic chain ladder reserves. Neil Covington Director of Solutions Management GI
Analytics Software Beyond deterministic chain ladder reserves Neil Covington Director of Solutions Management GI Objectives 2 Contents 01 Background 02 Formulaic Stochastic Reserving Methods 03 Bootstrapping
More informationA.dr.rwarded to foreiirti count rie will be f 7 SOperann.. rsri--.-j- -.?- .JULY. 12, lsiii).,11,111. yc:tl crst.iif. lit. J. lor Sale... Kb l.
E E b g b E x Y b p p g b 2 x $ p 2 p p 6 p x b b p x p pp 5 b x b p Y Yg g pg 2 Dp g pb? xp p g G 2 p p x D D p 59 E 9pp b b x xp D p p? 8 5 2 pp E x z b x? p p Z 2 p p x p 9 p x p p EE E EY E G E p EQ
More informationMarsh Model. Propofol
Marsh Model Propofol This work was supported by FEDER founds through COMPETE-Operational Programme Factors of Competitiveness ( Programa Operacional Factores de Competitividade") and by Portuguese founds
More information